The cost of Lumryz can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Lumryz. As with all medications ...

Specifically: In Q1 2025 patient demand metrics for LUMRYZ™, Avadel’s innovative narcolepsy medication with a market potential of a billion dollars in peak annual sales, all improved versus Q4 ...

LUMRYZ is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at ...

Specifically: In Q1 2025 patient demand metrics for LUMRYZ™, Avadel’s innovative narcolepsy medication with a market potential of a billion dollars in peak annual sales, all improved versus Q4 2024.

REVITALYZTM, the Company's Phase 3 pivotal trial studying LUMRYZ in Idiopathic Hypersomnia (IH), is on track to complete enrollment in the second half of 2025. Avadel has initiated four patent ...

During the 24th Annual Needham Virtual Healthcare Conference, the company confirmed that Q1 2025 patient demand metrics for LUMRYZ™ have shown improvement over the last quarter of 2024.

DUBLIN - Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company specializing in innovative pharmaceuticals with impressive gross profit margins of 91%, announced today that patient demand for its ...